NASDAQ:INMD InMode (INMD) Stock Forecast, Price & News $30.46 -0.49 (-1.58%) (As of 09/29/2023 ET) Add Compare Share Share Today's Range$30.08▼$31.3950-Day Range$30.46▼$45.0352-Week Range$28.51▼$48.25Volume2.15 million shsAverage Volume1.11 million shsMarket Capitalization$2.53 billionP/E Ratio14.23Dividend YieldN/APrice Target$51.67 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesShort InterestSocial Media InMode MarketRank™ ForecastAnalyst RatingModerate Buy2.83 Rating ScoreUpside/Downside69.6% Upside$51.67 Price TargetShort InterestBearish9.47% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.80Based on 8 Articles This WeekInsider TradingN/AProj. Earnings Growth15.51%From $2.45 to $2.83 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.49 out of 5 starsMedical Sector179th out of 972 stocksElectromedical Equipment Industry7th out of 20 stocks 3.4 Analyst's Opinion Consensus RatingInMode has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $51.67, InMode has a forecasted upside of 69.6% from its current price of $30.46.Amount of Analyst CoverageInMode has only been the subject of 3 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted9.47% of the outstanding shares of InMode have been sold short.Short Interest Ratio / Days to CoverInMode has a short interest ratio ("days to cover") of 6.2.Change versus previous monthShort interest in InMode has recently increased by 3.97%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldInMode does not currently pay a dividend.Dividend GrowthInMode does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for INMD. Previous Next 3.2 News and Social Media Coverage News SentimentInMode has a news sentiment score of 0.80. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for InMode this week, compared to 4 articles on an average week.Search InterestOnly 49 people have searched for INMD on MarketBeat in the last 30 days. This is a decrease of -38% compared to the previous 30 days.MarketBeat Follows13 people have added InMode to their MarketBeat watchlist in the last 30 days. This is an increase of 18% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, InMode insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.92% of the stock of InMode is held by insiders.Percentage Held by Institutions65.49% of the stock of InMode is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for InMode are expected to grow by 15.51% in the coming year, from $2.45 to $2.83 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of InMode is 14.23, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 117.60.Price to Earnings Ratio vs. SectorThe P/E ratio of InMode is 14.23, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 122.55.Price to Book Value per Share RatioInMode has a P/B Ratio of 4.56. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About InMode (NASDAQ:INMD) StockInMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures. It also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions, as well as hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. InMode Ltd. was incorporated in 2008 and is headquartered in Yokneam, Israel.Read More INMD Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart INMD Stock News HeadlinesSeptember 30, 2023 | americanbankingnews.comInMode Sees Unusually High Options Volume (NASDAQ:INMD)September 29, 2023 | americanbankingnews.comInMode (NASDAQ:INMD) vs. Vivani Medical (NASDAQ:VANI) Head-To-Head ReviewOctober 1, 2023 | Behind the Markets (Ad)The World's First "$20 Trillion Drug?" One small biotech holds the key to a revolution in treating Alzheimer's disease. Jeff Bezos, Goldman Sachs & Big Pharma giants have invested billions into this unknown biotech. Our research proves that anyone who gets in today could see 113,000% gains! Get the name of the stock here >>>September 27, 2023 | msn.comInMode: Bullish Support Failed To MaterializeSeptember 27, 2023 | seekingalpha.comInMode: Strong Net Cash Position Sets The Stage For Opportunistic BuybacksSeptember 26, 2023 | finance.yahoo.comInMode (INMD) Stock Moves -0.52%: What You Should KnowSeptember 20, 2023 | finance.yahoo.comIs Most-Watched Stock InMode Ltd. (INMD) Worth Betting on Now?September 6, 2023 | finance.yahoo.comInMode Ltd. (INMD) is Attracting Investor Attention: Here is What You Should KnowOctober 1, 2023 | Behind the Markets (Ad)The World's First "$20 Trillion Drug?" One small biotech holds the key to a revolution in treating Alzheimer's disease. Jeff Bezos, Goldman Sachs & Big Pharma giants have invested billions into this unknown biotech. Our research proves that anyone who gets in today could see 113,000% gains! Get the name of the stock here >>>September 4, 2023 | finance.yahoo.comIs HealthEquity (HQY) Outperforming Other Medical Stocks This Year?September 4, 2023 | seekingalpha.comInMode: Be Greedy When Others Are FearfulAugust 24, 2023 | msn.comInMode: Prolonged Valuation Slump Is A Buying OpportunityAugust 18, 2023 | finance.yahoo.comInMode Ltd. (INMD) Is a Trending Stock: Facts to Know Before Betting on ItAugust 11, 2023 | finance.yahoo.comGot $5,000? Here's 3 Reasons to Buy InMode Stock Right NowAugust 9, 2023 | msn.comThis 1 Number Shows Why InMode Stock Is a BuyAugust 2, 2023 | msn.comInmode (INMD) Price Target Increased by 17.87% to 56.51August 1, 2023 | finance.yahoo.comHere's Why We Think InMode (NASDAQ:INMD) Might Deserve Your Attention TodayJuly 29, 2023 | finance.yahoo.comHere's Why I'm Buying (More) InMode Stock in AugustJuly 28, 2023 | msn.comBaird Maintains Inmode (INMD) Outperform RecommendationJuly 28, 2023 | finance.yahoo.comInMode Ltd. (NASDAQ:INMD) Q2 2023 Earnings Call TranscriptJuly 28, 2023 | finance.yahoo.comInMode (INMD) Q2 2023 Earnings Call TranscriptJuly 27, 2023 | finance.yahoo.comInMode Reports Second Quarter 2023 Financial Results; Record Quarterly Revenue of $136.1M Represents 20% Year-Over-Year GrowthJuly 27, 2023 | finance.yahoo.comInMode (INMD) Q2 Earnings and Revenues Beat EstimatesJuly 27, 2023 | finance.yahoo.comAre Medical Stocks Lagging InMode (INMD) This Year?July 25, 2023 | finance.yahoo.comInMode (INMD) to Post Q2 Earnings: What's in the Cards?July 19, 2023 | finance.yahoo.comInvestors Heavily Search InMode Ltd. (INMD): Here is What You Need to KnowJuly 18, 2023 | finance.yahoo.comInstitutional investors control 62% of InMode Ltd. (NASDAQ:INMD) and were rewarded last week after stock increased 13%See More Headlines Receive INMD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for InMode and its competitors with MarketBeat's FREE daily newsletter. Email Address INMD Company Calendar Last Earnings7/27/2023Today10/01/2023Next Earnings (Estimated)10/26/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Electromedical equipment Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:INMD CUSIPN/A CIK885988 Webwww.inmodemd.com Phone972-4909-7470FaxN/AEmployees480Year Founded2008Price Target and Rating Average Stock Price Forecast$51.67 High Stock Price Forecast$61.00 Low Stock Price Forecast$40.00 Forecasted Upside/Downside+69.6%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)$2.14 Trailing P/E Ratio14.23 Forward P/E Ratio12.43 P/E GrowthN/ANet Income$161.52 million Net Margins36.77% Pretax Margin44.98% Return on Equity35.03% Return on Assets31.10% Debt Debt-to-Equity RatioN/A Current Ratio11.84 Quick Ratio11.21 Sales & Book Value Annual Sales$454.27 million Price / Sales5.56 Cash Flow$2.18 per share Price / Cash Flow13.99 Book Value$6.68 per share Price / Book4.56Miscellaneous Outstanding Shares82,980,000Free Float77,236,000Market Cap$2.53 billion OptionableNot Optionable Beta2.11 Social Links 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Yair Malca (Age 45)Chief Financial Officer Comp: $474kMr. Alon YaariVP of OperationsDr. Michael Kreindel (Age 55)CTO & Director Comp: $221kMs. Nava Tal-LaunerChief Information OfficerMr. Shakil Lakhani (Age 40)Pres of North America Comp: $2.97MMr. Moshe Mizrahy (Age 70)Chairman & CEO Dr. Spero Theodorou M.D. (Age 51)Chief Medical Officer More ExecutivesKey CompetitorsIntegerNYSE:ITGRLivaNovaNASDAQ:LIVNCONMEDNYSE:CNMDTransMedics GroupNASDAQ:TMDXMasimoNASDAQ:MASIView All CompetitorsInstitutional OwnershipPortside Wealth Group LLCBought 12,580 shares on 9/1/2023Ownership: 0.015%Wolverine Trading LLCSold 9,300 shares on 8/23/2023Ownership: 0.000%Osaic Holdings Inc.Bought 22,322 shares on 8/21/2023Ownership: 0.362%California State Teachers Retirement SystemBought 28,376 shares on 8/21/2023Ownership: 0.129%Legato Capital Management LLCBought 29,047 shares on 8/18/2023Ownership: 0.035%View All Institutional Transactions INMD Stock - Frequently Asked Questions Should I buy or sell InMode stock right now? 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for InMode in the last twelve months. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" INMD shares. View INMD analyst ratings or view top-rated stocks. What is InMode's stock price forecast for 2023? 6 brokers have issued 1 year price targets for InMode's shares. Their INMD share price forecasts range from $40.00 to $61.00. On average, they expect the company's share price to reach $51.67 in the next twelve months. This suggests a possible upside of 69.6% from the stock's current price. View analysts price targets for INMD or view top-rated stocks among Wall Street analysts. How have INMD shares performed in 2023? InMode's stock was trading at $35.70 at the beginning of 2023. Since then, INMD shares have decreased by 14.7% and is now trading at $30.46. View the best growth stocks for 2023 here. When is InMode's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, October 26th 2023. View our INMD earnings forecast. How were InMode's earnings last quarter? InMode Ltd. (NASDAQ:INMD) released its earnings results on Thursday, July, 27th. The healthcare company reported $0.65 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.65. The healthcare company had revenue of $136.08 million for the quarter, compared to the consensus estimate of $135.80 million. InMode had a net margin of 36.77% and a trailing twelve-month return on equity of 35.03%. What ETFs hold InMode's stock? ETFs with the largest weight of InMode (NASDAQ:INMD) stock in their portfolio include Acquirers Fund ETF (ZIG), BlueStar Israel Technology ETF (ITEQ), ARK Israel Innovative Technology ETF (IZRL), VanEck Israel ETF (ISRA) and iShares MSCI Israel ETF (EIS).Vident International Equity Strategy ETF (VIDI). When did InMode's stock split? InMode shares split on Thursday, September 30th 2021. The 2-1 split was announced on Friday, September 17th 2021. The newly issued shares were distributed to shareholders after the market closes on Monday, September 27th 2021. An investor that had 100 shares of stock prior to the split would have 200 shares after the split. What guidance has InMode issued on next quarter's earnings? InMode updated its FY23 earnings guidance on Thursday, July, 27th. The company provided earnings per share guidance of $2.62-$2.66 for the period, compared to the consensus earnings per share estimate of $2.64. The company issued revenue guidance of $530-$540 million, compared to the consensus revenue estimate of $534.01 million. What is Moshe Mizrahy's approval rating as InMode's CEO? 1 employees have rated InMode Chief Executive Officer Moshe Mizrahy on Glassdoor.com. Moshe Mizrahy has an approval rating of 100% among the company's employees. This puts Moshe Mizrahy in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of InMode own? Based on aggregate information from My MarketBeat watchlists, some companies that other InMode investors own include NVIDIA (NVDA), Alibaba Group (BABA), Salesforce (CRM), Micron Technology (MU), AbbVie (ABBV), Advanced Micro Devices (AMD), Block (SQ), Tesla (TSLA), DocuSign (DOCU) and PayPal (PYPL). When did InMode IPO? (INMD) raised $75 million in an initial public offering on Thursday, August 8th 2019. The company issued 5,000,000 shares at $14.00-$16.00 per share. Barclays, UBS Investment Bank and Canaccord Genuity served as the underwriters for the IPO and Baird was co-manager. What is InMode's stock symbol? InMode trades on the NASDAQ under the ticker symbol "INMD." How do I buy shares of InMode? Shares of INMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is InMode's stock price today? One share of INMD stock can currently be purchased for approximately $30.46. How much money does InMode make? InMode (NASDAQ:INMD) has a market capitalization of $2.53 billion and generates $454.27 million in revenue each year. The healthcare company earns $161.52 million in net income (profit) each year or $2.14 on an earnings per share basis. How many employees does InMode have? The company employs 480 workers across the globe. Does InMode have any subsidiaries? The following companies are subsidiares of InMode: Guangzhou InMode Medical Technology Ltd., InMode Asia Limited., InMode India Private Limited, InMode Japan KK, InMode M.D. Ltd., Invasix Corp., Invasix Iberia S.L., Invasix Inc., and Invasix UK Ltd..Read More How can I contact InMode? InMode's mailing address is TAVOR BUILDING SHAAR YOKNEAM POB 533, YOKNEAM L3, 2069200. The official website for the company is www.inmodemd.com. The healthcare company can be reached via phone at 972-4909-7470 or via email at ir@inmodemd.com. This page (NASDAQ:INMD) was last updated on 10/1/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding InMode Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.